Daewon Pharmaceutical: 'Oral Obesity Drug Candidate Achieves Three Times Higher Absorption Rate'
Predicted impact: Low
Preclinical oral obesity candidate absorption improvement; early stage with small revenue relevance.
Comments
No comments yet. Start the conversation.
Comments are people's own views. Nothing here is financial advice.